NEW YORK AND OSAKA (June 21, 2016) — TB Alliance and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; “Takeda”) announced
NEW YORK AND GENEVA (April 20, 2016) – TB Alliance and the Medicines Patent Pool (MPP) today announced a Memorandum
NEW YORK, NY (March 11, 2016)—TB Alliance has announced that it has stopped the clinical development program for the tuberculosis
Medication simplifies and improves treatment for 1 million children with TB Medicines come in dispersible fixed-dose combinations at the correct
TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant
TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and
Critical Path to TB Drug Regimens (CPTR), an initiative that brings together the world’s leading pharmaceutical companies, product development sponsors,
TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis (TB),
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard
* STAND trial will take place in approximately 50 study sites in Africa, Asia, Caribbean, Eastern Europe, and Latin America
